Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Daiichi Sankyo And AstraZeneca's ENHERTU Demonstrates Statistically Significant Improvement In Invasive Disease-Free Survival Versus T-DM1 In DESTINY-Breast05 Phase 3 Trial

Author: Benzinga Newsdesk | September 29, 2025 01:59am
  • Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca's ENHERTU in HER2 positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
  • Results from the DESTINY-Breast05 and DESTINY-Breast11 trials will be presented at ESMO 2025 in a Presidential Symposium
  • Plans for regulatory submissions are underway

Posted In: AZN DSNKY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist